Unique technology aims to restore the body’s
ability to counter-regulate hypoglycemia.
Zucara’s novel peptide antagonists have demonstrated potential.
LEARN MORE
Sitka Biopharma is addressing the absorption challenges of
current chemotherapeutics on its quest to develop the first
front line chemotherapeutic for intermediate- to high-risk
bladder cancer.
Sitka Biopharma is addressing the absorption challenges of
current chemotherapeutics on its quest to develop the first
front line chemotherapeutic for intermediate- to high-risk
bladder cancer.
Zucara Therapeutics Inc. is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in people with diabetes. Preventing hypoglycemia will dramatically change diabetes disease management, improving both patient health and quality of life.